These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

316 related articles for article (PubMed ID: 23325135)

  • 1. [Budgetary impact for the National Health System of apixaban prophylaxis of venous thromboembolism in patients undergoing total knee or hip replacement].
    Gómez Arrayas I; Suárez Fernández C; Gómez Cerezo JF; Betegón Nicolás L; de Salas-Cansado M; Rubio-Terrés C
    Rev Esp Salud Publica; 2012 Dec; 86(6):601-12. PubMed ID: 23325135
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-Effectiveness of Different Strategies for the Prevention of Venous Thromboembolism After Total Hip Replacement in China.
    Yan X; Gu X; Xu Z; Lin H; Wu B
    Adv Ther; 2017 Feb; 34(2):466-480. PubMed ID: 28000167
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost Effectiveness of Apixaban and Enoxaparin for the Prevention of Venous Thromboembolism After Total Knee Replacement in China.
    Yan X; Gu X; Zhou L; Lin H; Wu B
    Clin Drug Investig; 2016 Dec; 36(12):1001-1010. PubMed ID: 27581246
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and Efficacy of New Anticoagulants for the Prevention of Venous Thromboembolism After Hip and Knee Arthroplasty: A Meta-Analysis.
    Venker BT; Ganti BR; Lin H; Lee ED; Nunley RM; Gage BF
    J Arthroplasty; 2017 Feb; 32(2):645-652. PubMed ID: 27823844
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of Apixaban Versus Other Oral Anticoagulants for the Initial Treatment of Venous Thromboembolism and Prevention of Recurrence.
    Lanitis T; Leipold R; Hamilton M; Rublee D; Quon P; Browne C; Cohen AT
    Clin Ther; 2016 Mar; 38(3):478-93.e1-16. PubMed ID: 26922297
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Economic Evaluations of New Oral Anticoagulants for the Prevention of Venous Thromboembolism After Total Hip or Knee Replacement: A Systematic Review.
    Brockbank J; Wolowacz S
    Pharmacoeconomics; 2017 May; 35(5):517-535. PubMed ID: 28185212
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Apixaban versus enoxaparin in the prevention of venous thromboembolism following total knee arthroplasty: a single-centre, single-surgeon, retrospective analysis.
    King DA; Pow RE; Dickison DM; Vale PR
    Intern Med J; 2016 Sep; 46(9):1030-7. PubMed ID: 27246450
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Benefit-risk assessment of rivaroxaban versus enoxaparin for the prevention of venous thromboembolism after total hip or knee arthroplasty.
    Levitan B; Yuan Z; Turpie AG; Friedman RJ; Homering M; Berlin JA; Berkowitz SD; Weinstein RB; DiBattiste PM
    Vasc Health Risk Manag; 2014; 10():157-67. PubMed ID: 24707185
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost effectiveness of new oral anticoagulants for stroke prevention in patients with atrial fibrillation in two different European healthcare settings.
    Verhoef TI; Redekop WK; Hasrat F; de Boer A; Maitland-van der Zee AH
    Am J Cardiovasc Drugs; 2014 Dec; 14(6):451-62. PubMed ID: 25326294
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differences in Reported Outcomes in Industry-Funded vs Nonfunded Studies Assessing Thromboprophylaxis After Total Joint Arthroplasty.
    Groff H; Azboy I; Parvizi J
    J Arthroplasty; 2018 Nov; 33(11):3398-3401. PubMed ID: 30017220
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative efficacy and safety of anticoagulants for prevention of venous thromboembolism after hip and knee arthroplasty.
    Hur M; Park SK; Koo CH; Jung ED; Kang P; Kim WH; Kim JT; Jung CW; Bahk JH
    Acta Orthop; 2017 Dec; 88(6):634-641. PubMed ID: 28787226
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low molecular weight heparin versus other anti-thrombotic agents for prevention of venous thromboembolic events after total hip or total knee replacement surgery: a systematic review and meta-analysis.
    Lu X; Lin J
    BMC Musculoskelet Disord; 2018 Sep; 19(1):322. PubMed ID: 30193575
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A cost-utility analysis of dabigatran, enoxaparin, and usual care for venous thromboprophylaxis after hip or knee replacement surgery in Thailand.
    Kotirum S; Chongmelaxme B; Chaiyakunapruk N
    J Thromb Thrombolysis; 2017 Feb; 43(2):252-262. PubMed ID: 27704332
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of different anticoagulant drugs on the prevention of complications in patients after arthroplasty: A network meta-analysis.
    Gao JH; Chu XC; Wang LL; Ning B; Zhao CX
    Medicine (Baltimore); 2017 Oct; 96(40):e8059. PubMed ID: 28984761
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of apixaban versus low molecular weight heparin/vitamin k antagonist for the treatment of venous thromboembolism and the prevention of recurrences.
    Lanitis T; Leipold R; Hamilton M; Rublee D; Quon P; Browne C; Cohen AT
    BMC Health Serv Res; 2017 Jan; 17(1):74. PubMed ID: 28114939
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness Analysis for Apixaban in the Acute Treatment and Prevention of Venous Thromboembolism in the Netherlands.
    de Jong LA; Dvortsin E; Janssen KJ; Postma MJ
    Clin Ther; 2017 Feb; 39(2):288-302.e4. PubMed ID: 28139289
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative Effectiveness and Safety of Drug Prophylaxis for Prevention of Venous Thromboembolism After Total Knee Arthroplasty.
    Cafri G; Paxton EW; Chen Y; Cheetham CT; Gould MK; Sluggett J; Bini SA; Khatod M
    J Arthroplasty; 2017 Nov; 32(11):3524-3528.e1. PubMed ID: 28634095
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antithrombotic prophylaxis following total hip arthroplasty: a level I Bayesian network meta-analysis.
    Migliorini F; Maffulli N; Velaj E; Bell A; Kämmer D; Hildebrand F; Hofmann UK; Eschweiler J
    J Orthop Traumatol; 2024 Jan; 25(1):1. PubMed ID: 38194191
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low-Molecular-Weight Heparin and the Relative Risk of Surgical Site Bleeding Complications: Results of a Systematic Review and Meta-Analysis of Randomized Controlled Trials of Venous Thromboprophylaxis in Patients After Total Joint Arthroplasty.
    Suen K; Westh RN; Churilov L; Hardidge AJ
    J Arthroplasty; 2017 Sep; 32(9):2911-2919.e6. PubMed ID: 28522244
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incidence of symptomatic venous thromboembolism in 2372 knee and hip replacement patients after discharge: data from a thromboprophylaxis registry in Montreal, Canada.
    Senay A; Trottier M; Delisle J; Banica A; Benoit B; Laflamme GY; Malo M; Nguyen H; Ranger P; Fernandes JC
    Vasc Health Risk Manag; 2018; 14():81-89. PubMed ID: 29780248
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.